ChiCTR1900021050
尚未开始
/
/
/
2019-01-15
/
/
糖尿病
糖尿病與肩膊功能、肌肉力量、柔韌度及超聲波的評估
糖尿病與肩膊功能、肌肉力量、柔韌度及超聲波的評估
臨床及超聲波評估糖尿病與肩膊功能、肌肉力量、柔韌度
单臂
其它
N/A
N/A
Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong
/
100
/
1990-01-01
1990-01-01
/
1. aged 50 or above; 2. medically diagnosed with Type 2 diabetes; 3. able to sit, stand and walk independently, will be recruited.;
请登录查看1. History of central nervous dysfunction or comorbidities within 6 months (e.g. Heart attack, myocardial infarction, angina, peripheral artery disease, uncontrolled arrhythmias, uncontrolled hypertension, uncontrolled diabetes mellitus, asthmatic exacerbation, COPD exacerbation, active cancer on chemotherapy/radiotherapy, tuberculosis on medication, infectious disease, or any other conditions as declared unfit by a medical officer); 2. Significant musculoskeletal deformity or acute orthopaedics conditions (e.g. Recent fall/repeated falls, recent prolapsed intervertebral disc, severe spinal stenosis, recent joint replacement, severe OA knee(s)/hip(s), obvious limb deformity, presence of arthritis with pain limiting mobility, severe scoliosis, or any other conditions as declared unfit by a medical officer); 3. Neurological conditions (e.g. Stroke, frequent epilepsy, Parkinsonism, gait disturbance, recent head injury, cognitive impairment or any other conditions as declared unfit by a medical officer); 4. History or evidence of vestibular dysfunction; 5. Total blindness/severe visual impairment.;
请登录查看香港中文大學威爾斯親王醫院骨科與創傷學系
/
香港中文大學威爾斯親王醫院骨科與創傷學系的其他临床试验
香港中文大學威爾斯親王醫院骨科與創傷學系的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

